Park National Corp OH decreased its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 4.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 99,880 shares of the company’s stock after selling 4,351 shares during the quarter. Park National Corp OH’s holdings in Zoetis were worth $17,200,000 as of its most recent filing with the SEC.
A number of other large investors have also made changes to their positions in ZTS. Fairfield Bush & CO. bought a new stake in shares of Zoetis in the 1st quarter worth approximately $134,000. Sequoia Financial Advisors LLC lifted its position in Zoetis by 5.3% in the first quarter. Sequoia Financial Advisors LLC now owns 4,166 shares of the company’s stock worth $786,000 after purchasing an additional 211 shares during the period. Candriam Luxembourg S.C.A. boosted its stake in Zoetis by 3.9% during the first quarter. Candriam Luxembourg S.C.A. now owns 51,581 shares of the company’s stock worth $9,727,000 after buying an additional 1,914 shares in the last quarter. Covestor Ltd increased its holdings in Zoetis by 102.8% in the 1st quarter. Covestor Ltd now owns 724 shares of the company’s stock valued at $137,000 after buying an additional 367 shares during the period. Finally, Merit Financial Group LLC increased its holdings in Zoetis by 92.8% in the 1st quarter. Merit Financial Group LLC now owns 2,342 shares of the company’s stock valued at $442,000 after buying an additional 1,127 shares during the period. Institutional investors and hedge funds own 89.47% of the company’s stock.
Zoetis Stock Performance
Shares of NYSE:ZTS opened at $182.00 on Thursday. The business has a fifty day moving average of $182.85 and a 200-day moving average of $174.97. The firm has a market cap of $83.78 billion, a PE ratio of 38.24, a price-to-earnings-growth ratio of 3.02 and a beta of 0.78. The company has a debt-to-equity ratio of 1.42, a quick ratio of 1.97 and a current ratio of 3.50. Zoetis Inc. has a twelve month low of $124.15 and a twelve month high of $194.99.
Insider Buying and Selling
In other news, EVP Robert J. Polzer sold 1,179 shares of Zoetis stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $189.94, for a total value of $223,939.26. Following the completion of the sale, the executive vice president now directly owns 2,353 shares of the company’s stock, valued at approximately $446,928.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Robert J. Polzer sold 1,179 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $189.94, for a total value of $223,939.26. Following the transaction, the executive vice president now owns 2,353 shares in the company, valued at $446,928.82. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kristin C. Peck sold 13,000 shares of Zoetis stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $179.97, for a total value of $2,339,610.00. Following the completion of the sale, the chief executive officer now owns 56,843 shares of the company’s stock, valued at $10,230,034.71. The disclosure for this sale can be found here. Insiders sold 15,102 shares of company stock worth $2,741,661 in the last quarter. Insiders own 0.12% of the company’s stock.
Analyst Ratings Changes
ZTS has been the topic of several recent research reports. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 2nd. HSBC started coverage on Zoetis in a research note on Wednesday, September 6th. They issued a “buy” rating and a $230.00 price objective on the stock. Piper Sandler raised their target price on Zoetis from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Monday, August 14th. The Goldman Sachs Group upped their price target on Zoetis from $204.00 to $213.00 and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $205.00 price objective on shares of Zoetis in a report on Tuesday. Ten research analysts have rated the stock with a buy rating, According to MarketBeat, Zoetis currently has a consensus rating of “Buy” and a consensus target price of $225.13.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
- Five stocks we like better than Zoetis
- How to Start Investing in Real Estate
- WeWork Stock Soars: Meme Stock Madness or Mirage?
- How to Analyze Restaurant Stocks
- 3 Low-Cost ETFs That Are Crushing SPY
- What Are Dividend Champions? How to Invest in the Champions
- Shutterstock is the Value Stock they don’t want you to know about
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.